News Release

Ultrasound may better classify ovarian tumors

Peer-Reviewed Publication

Journal of the National Cancer Institute

Experts examining patterns in ultrasound images can more accurately classify ovarian tumors as benign or malignant than can pre-surgical blood tests, according to a study published online in the Nov. 13 Journal of the National Cancer Institute.

An elevated level of the protein CA-125 in blood is considered an indicator of whether an ovarian tumor is benign or malignant. This measure, however, can often be inaccurate. Another option is an ultrasound examination of the tumor. An experienced ultrasound examiner can often accurately classify an ovarian tumor using a method of pattern recognition.

Dirk Timmerman, M.D., Ph.D., of Katholieke Universiteit Leuven in Belgium and colleagues conducted a prospective study of 1,066 women to compare the ability of these two methods to discriminate between benign and malignant ovarian tumors. All of the women had an ultrasound examination within 120 days of their surgery to remove the tumor. Of these women, 809 had given blood samples before their surgery, and these samples were later analyzed for CA-125.

They found that experienced ultrasound examiners correctly classified 93 percent of the tumors as benign or malignant, while CA-125 levels correctly classified 83 percent of tumors at best.

“We hope our results will encourage responsible parties to expend more effort and more resources to educate and train those who perform gynecologic ultrasound examinations, so that the potential of the ultrasound technique can be maximized,” the authors write.

###

Contact: Luc West, communications office, Katholieke Universiteit Leuven, Luc.West@dcom.kuleuven.be, +32 16 323712 or +32 479983792 (mobile)

Contact: Liz Savage, jncimedia@oxfordjournals.org, 301-841-1287, Journal of the National Cancer Institute

Citations: Van Calster B, Timmerman D, Bourne T, Testa AC, et al. Discrimination Between Benign and Malignant Adnexal Masses by Specialist Ultrasound Examination Versus Serum CA-125. J Natl Cancer Inst 2007; 99: 1706-1714

Note to Reporters:

We have started up an e-mail list to alert reporters when papers are available on the EurekAlert site. If you would be interested on being on this list, please let us know at jncimedia@oxfordjournals.org. The content will continue to be available through EurekAlert’s e-mail system and our EurekAlert page.

The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jnci.oxfordjournals.org/.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.